Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the third quarter of 2023.
Sales of MNOK 32.1 in 3Q23, up 39% vs 3Q22 (29% organic growth). Revenue of MNOK 97.7 YTD 2023 up 33% (21% organic growth) vs YTD 2022.
EBITDA of NOK 1.2 million in 3Q23 and NOK 4.3 million YTD 2023, compared to EBITDA of NOK -6.1 million in 3Q22 and NOK -11.5 million YTD 2022.
Cystatin C sales increased 90% in 3Q23 compared to 3Q22 and 39% YTD 2023 vs YTD 2022.
Launch of Gentian Retinol-Binding Protein (RBP) Immunoassay. A new CE-marked turbidimetric instrument independent assay, with the key demand driver being the aging population and lifestyle associated diseases and deficiencies.
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.